Join Growin Stock Community!
Beta
Back to ABBV.US Analysis

Ticker

Value

empty

There is no following symbol in this watchlist.

  • Revenue by Segments
  • EPS
  • EPS Diluted
  • Revenue
  • Operation Income
  • Net Income
  • Operating Expenses
  • Cash Flow
  • Cash & Debt
  • Current Contract Liabilities
cash-and-debt-chart

ABBV Cash & Debt

This disclaimer is provided by TradingValley Inc. and includes any messages, news, research, analysis, prices or other information provided by the Company's website, the application "Growin App" and other services provided through the Company's website. It is only general market information for educational and investment decision-making reference, and does not constitute any investment advice. View Growin Disclaimer

As of Q1'26, AbbVie's cash and short-term investments stood at $9.39B USD, reflecting a notable rebound from the recent low of $5.26B in Q4'25, while total debt increased to $72.86B USD, up from $67.50B in the prior quarter. This latest position indicates improved liquidity relative to the end of 2025, though debt levels remain substantially higher than cash reserves. Over the period from Q2'23 to Q1'26, cash and short-term investments exhibited volatility, peaking at $18.07B in Q1'24 before declining sharply to a low of $5.26B in Q4'25, with an overall downward trend averaging around $9B in recent quarters. In contrast, debt levels showed relative stability, fluctuating between $59.39B and $74.00B, with a slight upward trajectory in the latest periods that has widened the net debt position to approximately $63.47B. This pattern suggests ongoing challenges in maintaining robust liquidity amid consistent debt obligations, potentially impacting financial flexibility for the pharmaceutical company.